激酶 - 翻译成英语

• kinase
• kinases

在 中文 中使用 激酶 的示例及其翻译为 英语

这药或抑制EGFR酪氨酸激酶是治疗常常会出现这样的癌症很有帮助。
Drugs that inhibit EGFR or tyrosine kinase enzymes are often helpful for treating such cancers.

有四种哺乳动物丙酮酸激酶同种型（PKM1，PKM2，PKR，PKL），并且每种同种型在文献中随时间具有多种名称。
There are four mammalian pyruvate kinase isoforms(PKM1, PKM2, PKR, PKL), and each isoform has had multiple designations over time in the literature.

LOXO-305针对布鲁顿酪氨酸激酶（BTK）的改变靶向癌症，旨在解决对目前可用的BTK抑制剂的获得性抗性。
LOXO-305 targets cancers with alterations to the Bruton's tyrosine kinase(BTK), and is designed to address acquired resistance to currently available BTK inhibitors.

激酶是催化磷酸基团转移到另一种蛋白质的蛋白质，这一过程称为磷酸化，这是蛋白质功能的关键。
Kinases are proteins that catalyze the transfer of a phosphate group to another protein, a process called phosphorylation that is key to a protein's function.

帕博西尼是一种新型的一流细胞周期蛋白依赖性激酶（CDK）4/6抑制剂，于2015年2月在美国被批准用于治疗晚期/转移性乳腺癌。
Palbociclib, a novel, first-in-class cyclin-dependent kinase(CDK) 4/6 inhibitor was approved in the USA in February 2015 for the treatment of advanced/metastatic breast cancer.

激酶是新陈代谢，细胞信号传导，蛋白质调节，细胞运输，分泌过程以及许多其他允许我们健康运作的细胞途径的关键参与者。
Kinases are key players in metabolism, cell signalling, protein regulation, cellular transport, secretory processes, and many other cellular pathways that allow us to function healthily.

重要的是，抑制CDK2（非其他细胞周期蛋白依赖性激酶CDK1/4/6）可有效诱导AML细胞系和5个原发性患者来源的AML样本的主要亚型细胞向粒细胞分化。
Importantly, inhibiting CDK2, but not other cyclin-dependent kinases CDK1/4/6, effectively induced granulocytic differentiation in AML cell lines and 5 major subtypes of primary patient-derived AML samples.

由于治疗BCR-ABL1-相关白血病特异性靶向酪氨酸激酶产生的蛋白质，这些人仍然可以监视随着量BCR-ABL1分子检测。
Since the treatment for BCR-ABL1-related leukemias specifically targets the tyrosine kinase protein produced, these people can still be monitored with quantitative BCR-ABL1 molecular testing.

这种相互作用诱导了Raf的激酶活性，导致MAPK/ERK(MEK)的直接磷酸化，其反过来磷酸化细胞外的信号相关激酶(ERK)。
This interaction induces the kinase activity of Raf leading to direct phosphorylation of MAPK/ERK(MEK), which in turn phosphorylates the extracellular signal-related kinase(ERK).

后期LTP是由基因表达和蛋白质合成所引发的变化所诱导的，这个过程由E-LTP期间激活的蛋白激酶（如MAPK）的持续激发而引起。
Late LTP is induced by changes in gene expression and protein synthesis brought about by the persistent activation of protein kinases activated during E-LTP, such as MAPK.

因此，研究人员已经越来越多地转向其他药物――如抗生素或小的、被称为酪氨酸激酶抑制剂的化合物，与它们一起使用。
So researchers have been increasingly turning to other medications, such as antibiotics or small compounds called tyrosine kinase inhibitors, to use with them.

此外，Torin1对mTOR比对PI3K(EC50=1800nM)的选择性高1000倍，比对450种其它蛋白激酶的结合选择性高100倍。
Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K(EC(50)= 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases.

已经鉴定了四种不同的IRAK样分子：两种活性激酶，IRAK-1和IRAK-4，以及两种非活性激酶，IRAK-2和IRAK-M。
In the meantime, four different IRAK-like molecules have been identified: two active kinases, IRAK-1 and IRAK-4, and two inactive kinases, IRAK-2 and IRAK-M.

Tideglusib（NP-12，NP031112）是一种有效、选择性且不可逆的[1]小分子非ATP竞争性糖原合酶激酶-3（GSK-3）抑制剂。
Tideglusib(NP-12, NP031112) is a potent, selective and irreversible[1] small molecule non-ATP-competitive glycogen synthase kinase 3(GSK-3) inhibitor.

在上世纪80年代末，Ciba？Geigy公司（现属于诺华集团）的科学家们启动了一系列寻找蛋白激酶抑制剂的项目。
In the late 1980s, scientists at Ciba Geigy(now part of the Novartis Group) launched a series of projects to find protein kinase inhibitors.

丝裂原蛋白激酶.
Mitogen- Activated Protein Kinases.

Polo样激酶抑制剂包括BI-2536等等。
Polo-like kinase inhibitors include BI-2536 and the like.

Kisqali（ribociclib）是一种激酶抑制剂。
KISQALI(ribociclib) is a kinase inhibitor.

深度学习能够快速识别有效的DDR1激酶.
Deep learning enables rapid identification of potent DDR1 kinase.

临床试验结果与新的蛋白激酶药物Idelalisib.
Clinical Trial Results with New Kinase Drugs Idelalisib.